Acorda to Present New Research on Novel Multiple Sclerosis and Epilepsy Therapies at American Academy of Neurology …

ARDSLEY, N.Y.--(BUSINESS WIRE)--

Acorda Therapeutics, Inc.(Nasdaq:ACOR) will present new research data at the 65th American Academy of Neurology Annual Meeting on AMPYRA(dalfampridine) Extended Release Tablets, 10 mg, an FDA-approved therapy indicated to improve walking in people with multiple sclerosis, and Diazepam Nasal Spray, an investigational therapy for the treatment of cluster seizures, also known as acute repetitive seizures, in people with epilepsy.

Acorda is focused on improving the lives of people with neurological disorders. We currently are developing seven therapies for a range of conditions, including multiple sclerosis, epilepsy and spinal cord injury, saidRon Cohen, M.D., Acorda Therapeutics President and CEO. Our presentations at AAN include new studies on AMPYRA and the first clinical data presented on Diazepam Nasal Spray. These studies have increased our understanding of the potential roles these therapies could have in addressing the urgent needs of patients with these conditions.

Data being presented on Acorda-developed therapies at the AAN annual meeting include:

More detailed information on scientific sessions and data presentations at the AAN annual meeting can be found on the conference website (http://www.aan.com/go/am13).

Important Safety Information

Do not take AMPYRA if you have ever had a seizure or have certain types of kidney problems.

Take AMPYRA exactly as prescribed by your doctor.

You could have a seizure even if you never had a seizure before. Your chance of having a seizure is higher if you take too much AMPYRA or if your kidneys have a mild decrease of function, which is common after age 50.

Your doctor may do a blood test to check how well your kidneys are working, if that is not known before you start taking AMPYRA.

More:
Acorda to Present New Research on Novel Multiple Sclerosis and Epilepsy Therapies at American Academy of Neurology ...